Overview

NCI Definition: A disorder characterized by proliferation of lymphocytes at various stages of differentiation. Lymphoproliferative disorders can be neoplastic (clonal, as in lymphomas and leukemias) or reactive (polyclonal, as in infectious mononucleosis). [1]

Lymphoproliferative disorders most frequently harbor alterations in KMT2D, CREBBP, TP53, BCL2, and TET2 [2].

Most Commonly Altered Genes in Lymphoproliferative Disorder

KMT2D Mutation, CREBBP Mutation, TP53 Mutation, TP53 c.217-c.1178 Missense, and TP53 Missense are the most common alterations in lymphoproliferative disorder [2].

Top Alterations in Lymphoproliferative Disorder

Disease Details

Parent(s)
Hematologic and Lymphocytic Disorder
Children
Atypical Lymphoproliferative Disorder, Immunodeficiency-Associated Lymphoproliferative Disorder, Benign Lymphoproliferative Disorder, and Lymphocytic Neoplasm
OncoTree Name
Lymphoid
OncoTree Code
LYMPH

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.